Table 1.
Long-Acting Drugs and Formulations with Potential Application to HIV Prevention
| Drug Class | Agent | Formulation | Development Stage |
|---|---|---|---|
| NRTI | Islatravir (MK-8591) | Monthly oral; Implant | Phase II/III (on hold) |
| TAF | Implant | Preclinical | |
| GS-9131 | Implant | Preclinical | |
| NNRTI | Elsulfavirine | Injectable | Preclinical (oral drug approved in Russia) |
| PI | Atazanavir | Injectable | Preclinical |
| Ritonavir | Injectable | Preclinical | |
| INSTI | Dolutegravir | Implant | Preclinical |
| Raltegravir | Injectable | Preclinical | |
| Entry Inhibitors | Albuvirtide | Intravenous and injectable | Approved in China |
| bNAbs (e.g., VRC01, VRC07) | Intravenous | Phase I/II/III | |
| Combinectin | Intravenous | Phase I | |
| Capsid Inhibitors | Lenacapavir | Oral and subcutaneous | Phase II/III |